Printer Friendly

U.S. BIOSCIENCE DISCLOSES ALLEGED CLASS ACTION SUIT

 U.S. BIOSCIENCE DISCLOSES ALLEGED CLASS ACTION SUIT
 WEST CONSHOHOCKEN, Pa., Feb. 4 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) today said that it is being sued by an alleged stockholder of the company and by an alleged purchaser of options to purchase the company's common stock, in a purported class action suit, under Section 10(b) of the Securities Exchange Act of 1934.
 The complaint was filed in the U.S. District Court of the Eastern District of Pennsylvania on Feb. 3, 1992, and also contains claims of state common law fraud and negligent misrepresentation. The complaint also names as a defendant Philip S. Schein, M.D., the company's chairman and chief executive officer.
 The complaint alleges that the defendants made misrepresentations concerning the likelihood of approval by the Food and Drug Administration of one of the company's drugs, Ethyol(R).
 The company and Dr. Schein believe that there is no merit to the allegations in the complaint, and they expect their legal counsel to file a response in the next several weeks.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer treatments, including four products in the final stages of development. One product, Hexalen(R), is approved in the United States for the treatment of ovarian cancer.
 -0- 2/4/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503; or Charles Versaggi of Versaggi & Associates, 408-358-4162, or 408-395-1877, for U.S. Bioscience/
 (UBS) CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU:


U.S. -- SJ002 -- 6857 02/04/92 16:12 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1992
Words:289
Previous Article:MAZDA MX-3 RECORDS BEST-EVER SALES MONTH
Next Article:CLEVELAND CLINIC PALLIATIVE CARE SERVICE HONORED
Topics:


Related Articles
Kaplan, Kilsheimer & Fox LLP Files Class Action on Behalf of Curative Health Services, Inc. Shareholders.
/C O R R E C T I O N -- Barrack, Rodos & Bacine/.
Levy and Levy, P.C. Announces Class Action Filed Against Transkaryotic Therapies, Inc.
Vicuron Pharmaceuticals Incorporated Misled Investors, Berger & Montague Alleges.
TKT Announces Purported Class Action Lawsuit.
Kaplan Fox Seeks to Recover Losses for Investors who Purchased Securities of GlaxoSmithKline PLC.
Kaplan Fox Seeks to Recover Losses for Investors who Purchased Securities of GlaxoSmithKline PLC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters